Description
Kadcyla is a medication that has been developed to treat a certain type of breast cancer known as HER2-positive breast cancer. It is a combination of two drugs, Trastuzumab and Emtansine, and is administered through injection.
The drug works by targeting the HER2 protein, which is found in high levels in this type of cancer. Trastuzumab works by attaching to the HER2 protein and blocking its ability to signal cells to divide and grow. Emtansine, on the other hand, works by entering the cancer cells and destroying them from the inside.
Kadcyla is typically administered once every three weeks and must be administered by a healthcare provider. The dosage prescribed will depend on the individual’s weight and overall health.
Studies have shown that Kadcyla can be effective in treating advanced HER2-positive breast cancer. In one study, patients who received Kadcyla had a longer progression-free survival rate and a higher overall response rate compared to those who received traditional chemotherapy.
Like any medication, Kadcyla is not without side effects. Some common side effects of Kadcyla include fatigue, nausea, muscle and joint pain, and a decrease in white blood cells. More serious side effects may include liver problems and heart failure.
It is important for patients to communicate with their healthcare provider about any side effects they may be experiencing and to attend all scheduled appointments to monitor their response to the medication.
In conclusion, Kadcyla has shown promise in treating HER2-positive breast cancer and is an important option for patients with this type of cancer. While it may come with side effects, it can help improve quality of life and overall survival for those who receive it. As always, patients should work closely with their healthcare provider to determine the best course of treatment for their individual needs.
Reviews
There are no reviews yet.